JinYi Connect, officially known as JinYi Connect Limited, is a subsidiary established in Hong Kong in 2025 by Index Ventures to expand into the Asian market. It aims to manage a dedicated Asia fund, focusing on investing in biomedical and technology startups in Asia. Leveraging its background advantages, the company will bring a new global venture capital system to Asian clients, supporting the development of biomedical and technology startups.

JinYi Connect focuses primarily on the development of the biomedical and technology startup sectors.

In the biomedical field, the company focuses on cutting-edge areas such as gene therapy, precision medicine, and digital health. Simultaneously, in the technology sector, it emphasizes disruptive technologies such as artificial intelligence, blockchain, and quantum computing. The company employs a unique investment strategy, combining Index Ventures' global network and localized operational advantages to provide comprehensive support to entrepreneurs, helping companies grow rapidly and achieve globalization.

In the technology startup sector, the company is committed to discovering promising technological innovation projects, deeply participating in the company's development process, helping companies refine their business models, and building efficient team structures.  By integrating resources from multiple parties, the company aims to provide its portfolio companies with one-stop services, from technology research and development to market expansion, and to create a sustainable ecosystem.